Welcome to our dedicated page for Humacyte news (Ticker: HUMA), a resource for investors and traders seeking the latest updates and insights on Humacyte stock.
Humacyte, Inc. reports commercial, clinical and regulatory developments for its bioengineered human tissue platform. The company’s first FDA-approved product, Symvess, is an acellular tissue engineered vessel indicated for treatment of extremity vascular trauma, while other ATEV applications remain part of its broader regenerative medicine pipeline.
Recurring updates include Symvess commercialization, hospital access and distribution arrangements, international regulatory submissions, and clinical work in arteriovenous access for hemodialysis patients. Humacyte also reports quarterly financial results, business-development activity, financing actions and leadership changes tied to its transition from platform development to commercial-stage biotechnology operations.
Humacyte (Nasdaq:HUMA) announced that its bioengineered vessel product Symvess is now under contract with the U.S. Department of Veterans Affairs’ Strategic Acquisition Center (SAC) through the Surgical Implant – Next Generation (SING) program.
This contract makes Symvess more easily accessible to 170 VA hospitals, SAC’s preferred sourcing sites, after SAC’s surgical committee product and value vetting. Symvess received FDA approval in December 2024 for extremity vascular trauma; for all other uses, it remains investigational and unapproved.
Humacyte (Nasdaq:HUMA) reported first quarter 2026 results and a business update. Symvess sales reached $0.5 million (29 units), up from $0.1 million (5 units) a year earlier. Contract revenue fell to $2,000 from $0.4 million.
The company received a $1.475 million minimum Symvess purchase commitment in Saudi Arabia, Israeli review acceptance for Symvess, and new U.S. Department of Defense funding. An interim Phase 3 hemodialysis readout is planned for June 11, 2026. A workforce restructuring is expected to save $14.3 million through 2026, with estimated $0.8 million in one-time charges. Net loss was $17.6 million, and cash, cash equivalents and restricted cash totaled $48.9 million at March 31, 2026.
Humacyte (Nasdaq:HUMA) appointed vascular surgeon Dr. Todd E. Rasmussen as Chief Surgical Officer. He will provide peer-to-peer scientific support, medical education, and technical insights to help optimize safe and effective implantation of Humacyte’s bioengineered vascular products, including Symvess, as clinical adoption and pipeline indications advance.
Dr. Rasmussen brings 28 years of U.S. Air Force experience, leadership roles at Mayo Clinic, and more than 350 peer-reviewed publications. He will maintain his clinical, educational, and administrative responsibilities at Mayo Clinic while serving separately at Humacyte.
Humacyte (Nasdaq: HUMA) will release its 2026 first quarter financial results for the period ended March 31, 2026 on May 13, 2026 and will host a webcast and conference call at 8:00 a.m. ET for a corporate and financial update.
The company is a commercial-stage developer of acellular, bioengineered human tissues; its ATEV received FDA approval in December 2024 for vascular trauma and continues in late-stage trials for AV access and PAD. Webcast and dial-in details are provided for investors.
Humacyte (Nasdaq: HUMA) will host a virtual key opinion leader event on April 28, 2026 at 8:00 AM ET to discuss the unmet need and treatment landscape for hemodialysis patients with end-stage renal disease and provide an overview of its Acellular Tissue Engineered Vessel (ATEV) in arteriovenous access.
The event features KOLs Prabir Roy-Chaudhury, MD, PhD, FASN, and Mohamad A. Hussain, MD, PhD, RPVI, FAHA, FRCSC, FACS, and will include a live Q&A. The ATEV remains investigational for uses beyond the FDA extremity vascular trauma approval; interim V012 Phase 3 top-line results are expected this quarter.
Humacyte (Nasdaq: HUMA) on April 24, 2026 realigned ex-U.S. commercial rights to Symvess through an amended distribution agreement with Fresenius Medical Care. The amendment grants Humacyte exclusive distribution rights outside the U.S., with Fresenius entitled to low-single-digit royalties on Humacyte's net non-U.S. sales. U.S. distribution terms remain unchanged. The realignment is intended to support Humacyte's planned international expansion, advance discussions with potential corporate partners for indication-specific and regional rights, and enable previously announced initiatives in the Kingdom of Saudi Arabia and Israel. For uses beyond the FDA-approved extremity vascular trauma indication, Symvess remains investigational and is not approved for sale by the FDA or other regulators.
Humacyte (Nasdaq: HUMA) appointed Jim Mercadante as Chief Commercial Officer on April 22, 2026.
Mercadante brings more than 25 years of medtech commercial experience to lead U.S. Symvess expansion and broader ATEV platform commercialization as the company advances toward a planned BLA filing in dialysis.
Humacyte (Nasdaq: HUMA) announced that the Israel Ministry of Health accepted its Marketing Authorization Application for Symvess (acellular tissue engineered vessel) for arterial trauma repair and set a 180-working-day review period.
Acceptance references existing FDA approval for extremity vascular trauma and is described as a step in planned global expansion of Symvess.
Humacyte (Nasdaq: HUMA) reported $0.5M Q4 revenue and $2.0M for 2025, including $1.4M of Symvess sales. The company received a $1.475M purchase commitment in Saudi Arabia, submitted a Marketing Authorization Application in Israel, and secured DoD funding support.
Key milestones: top-line interim result from the V012 Phase 3 hemodialysis study expected by early June 2026 and planned BLA filing in H2 2026. Cash was $50.5M at year-end, with subsequent equity proceeds and a $40M initial tranche from a $77.5M credit facility.
Humacyte (Nasdaq: HUMA) appointed Rick McElheny as Senior Vice President of Business Development effective March 26, 2026. McElheny brings more than 15 years of corporate development and alliance management experience and will lead efforts to expand collaborations to commercialize Humacyte’s bioengineered tissue pipeline.
His prior roles include SVP of Corporate Development at Clearside and founder/VP of corporate development at Vidara, where he led transactions including a $660 million sale and over $250 million in out‑licensing deals.